0000950170-24-041300.txt : 20240403 0000950170-24-041300.hdr.sgml : 20240403 20240403172300 ACCESSION NUMBER: 0000950170-24-041300 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240328 FILED AS OF DATE: 20240403 DATE AS OF CHANGE: 20240403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Winton Matthew CENTRAL INDEX KEY: 0001971400 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39397 FILM NUMBER: 24820157 MAIL ADDRESS: STREET 1: C/O INOZYME PHARMA, INC. STREET 2: 321 SUMMER STREET, SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inozyme Pharma, Inc. CENTRAL INDEX KEY: 0001693011 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 475129768 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 857-330-4340 MAIL ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: Inozyme Pharma, LLC DATE OF NAME CHANGE: 20161222 4 1 ownership.xml 4 X0508 4 2024-03-28 0001693011 Inozyme Pharma, Inc. INZY 0001971400 Winton Matthew C/O INOZYME PHARMA, INC. 321 SUMMER STREET SUITE 400 BOSTON MA 02210 false true false false COO false Common Stock 2024-03-28 5 A false 3188 3.33 A 3188 D Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of October 1, 2023 through March 31, 2024. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on October 2, 2023, the first trading day of the purchase period. /s/ Matthew Winton 2024-04-03